Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 SINGAPORE, May 8, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to...

Related Keywords

New Zealand , Singapore , Australia , Carlo Montagner , South East Asia , Richard Quek , Deciphera Pharmaceuticals , Singapore Health Sciences Authority , Corporate Affairs Emma Power , Health Sciences Authority , European Society For Medical Oncology Virtual Meeting , Gi Cancer Institute Australia , Specialised Therapeutics Asia , Executive Officer Carlo Montagner , Manager Communications , Specialised Therapeutics , Response Evaluation Criteria , Solid Tumors , Lancet Oncol , Product Information , Medical Oncology Virtual Meeting , Institute Australia , Clin Cancer ,